Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2025 08:55 ET | Source: PharmAla Biotech

PharmAla Issues Q2 Financial Statements

PharmAla releases Q2 financial statements showing increased customer deposits, shipments
March 24, 2025 09:00 ET | Source: PharmAla Biotech

PharmAla Contracts with Partner to Act as US Distributor

PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
March 21, 2025 09:00 ET | Source: PharmAla Biotech

PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington

PharmAla completes shipment of MDMA to University of Washington, to be used in a Narcissism clinical trial. It also appoints Ali Taghva as CCO.
March 03, 2025 09:01 ET | Source: PharmAla Biotech

PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study

PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
February 27, 2025 14:45 ET | Source: PharmAla Biotech

PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA

PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
January 20, 2025 08:55 ET | Source: PharmAla Biotech

PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel

PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
December 13, 2024 09:25 ET | Source: PharmAla Biotech

PharmAla Announces Private Placement

PharmAla announces private placement financing
October 21, 2024 09:25 ET | Source: PharmAla Biotech

PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA

PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
September 14, 2023 14:59 ET | Source: Optimi Health Corp.

Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a Canadian psychedelics drug research and formulation company, is pleased...